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Multiple human proteins have been shown to
both support and restrict viral replication, and
confirmation of virus-associated changes in
the expression of these genes is relevant for
future therapeutic efforts. In this study a well-
characterized panel of 49 individuals either
infected with HIV-1 or uninfected was com-
piled and analyzed for the effect of HIV in-
fection status, viral load, and antiretroviral
treatment on specific gene expression. mRNA
was extracted and reverse transcribed from
purified CD4þ cells, and quantitative real-time
PCR was utilized to scrutinize differences in
the expression of four host genes that have
been demonstrated to either stimulate (HSP90
and LEDGF/p75) or restrict (p21/WAF1 and
APOBEC3G) proviral integration. HIV infection
status was associated with slight to moderate
alterations in the expression of all four genes.
After adjusting for age, mRNA expression
levels of HSP90, LEDGF/p75 and APOBEC3G
were found to all be decreased in infected
patients compared to healthy controls by
1.43-, 1.26-, and 4.71-fold, respectively, while
p21/WAF1 expression was increased 2.35-fold.
Furthermore, individuals receiving raltegravir
exhibited a 1.28-fold reduction in LEDGF/p75
compared to those on non-raltegravir antire-
troviral treatment. Identification of these and
similar HIV-induced changes in gene expres-
sion may be valuable for delineating the
extent of host cell molecular mechanisms
stimulating viral replication. J. Med. Virol.
86:678–686, 2014.
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HIV-1 persists as a global epidemic with no known
cure. Over 30 antiretroviral drugs targeting various
stages of the viral life cycle have been developed to-
date [Broder, 2010], but the emergence of drug-resist-
ant viral strains has been a constant, insurmountable
problem facing patients, pharmaceutical scientists,
and clinicians alike since the initial prescription of
AZT almost three decades ago [Cozzi-Lepri et al., 2007;
Serrao et al., 2009]. The initial phase of HIV infection
is characterized by high levels of circulating HIV RNA
and a rapid decline in CD4þ T lymphocyte count
[Cadogan and Dalgleish, 2008; McMichael et al., 2010].
Following infection there is a state of chronic immune
activation, characterized by high T cell turnover,
apoptosis, and cell death. Activation of CD4þ T cells is
essential for HIV to establish a productive infection
[Zack et al., 1990; Bukrinsky et al., 1991; Zhou et al.,
2005], and a stable state of latent infection is thought
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to develop mainly as a subset of long-lived activated
cells reverts back to the resting state [Siliciano and
Greene, 2011]. Even intense pressure from HAART
has been unable to eradicate the virus from stable
latent reservoirs [Siliciano et al., 2003]. Productive
proviral integration by HIV-1 integrase (IN) is a
prerequisite for latency to occur, and multiple host
proteins have been discovered to assist or restrict this
enzymatic process [Al-Mawsawi and Neamati, 2007].
Of note, APOBEC3G and p21/WAF1 are host restric-
tion factors also shown to bind and inhibit IN [Luo
et al., 2007; Zhang et al., 2007]. On the other hand,
HSP90 has been shown to stimulate both HIV-1 tran-
scription and integration [O’Keeffe et al., 2000; Vozzolo
et al., 2010], and small-molecule HSP90 inhibitors
have shown antiviral effects and a reduction in inte-
gration efficiency [Vozzolo et al., 2010; Roesch et al.,
2012]. Similarly, LEDGF/p75 is a host cofactor of
integration that has been elegantly demonstrated to
tether IN to the host chromosome and promote integra-
tion into transcriptional active genomic regions [Cher-
epanov et al., 2003; Shun et al., 2007]. Discoveries such
as this have demonstrated that understanding the host
antiviral response and the full extent of HIV’s manipu-
lation of host cell machinery is crucial for therapeutic
innovation.
In this cross-sectional study, a well-characterized
panel of 49 individuals uninfected or infected with HIV-
1 was compiled and analyzed for the effect of various
parameters on the mRNA expression levels of HSP90,
LEDGF/p75, p21/WAF1, and APOBEC3G. Specific pa-
rameters that were scrutinized included subject sex,
ethnicity, HIV transmission status (behavioral or peri-
natal), HIV infection and exposure status, viral load,
and antiretroviral treatment. While sex, ethnicity,
exposure status, and transmission status were not asso-
ciated with age-adjusted mRNA expression changes,
subtle to significant differences in the expression of
each gene in subjects infected with HIV compared to
uninfected individuals were apparent. Additionally,
individuals infected with HIV that were treated with
raltegravir exhibited a reduction in LEDGF/p75 com-
pared to those on a non-raltegravir regimen.
METHODS
Study Design
Subjects were selected from a Natural History,
Long-term Follow-up and Pathogenesis Study of HIV
Infection at the Maternal, Child, Adolescent Center
for Infectious Diseases and Virology at the Los
Angeles County, and the University of Southern
California Medical Center in Los Angeles, CA. In-
formed consent was obtained for each patient in this
IRB-approved study. At each routine clinic visit, a
blood specimen was stored in the MCA repository for
future research. Additional specimens from unin-
fected subjects were provided by individuals volun-
teering for another IRB approved sub-study of the
Natural History Study.
Based on the availability of repository specimens
collected between 2008 and 2011, patients fitting
desired experimental criteria were selected and organ-
ized into groups with careful definition of clinical and
virologic parameters. The most recently collected speci-
men available for each subject was selected to be used
to measure gene expression. Subjects were chosen
based on their HIV infection status, HIV exposure
status, HIV viral load, and antiretroviral treatment
status. The goal was to select approximately 10
subjects in three groups of patients infected with HIV
based on their HIV viral load and treatment status,
and two groups of uninfected patients based on their
HIV exposure status. Among the patients infected with
HIV, the following were selected: (i) 15 patients who
received antiretroviral treatment and had an undetect-
able viral load (<50 copies/ml) for at least 2 years
(infected/treated/non-viremic); (ii) nine subjects who
also received antiretroviral treatment but who had a
high viral load at the time of specimen collection of
>10,000 copies/ml (infected/treated/high viral load);
and (iii) nine patients who were not receiving treat-
ment at the time of the specimen (infected/untreated).
Among the uninfected individuals, nine were exposed
perinatally to HIV but uninfected, and seven were
unexposed. Other variables collected in the Natural
History Study included antiretroviral drug regimen,
gender, age at the time of the specimen collection, sex,
ethnicity, perinatal versus behavioral mode of HIV
transmission, race/ethnicity, and CD4 count at the
time of the specimen collection.
Isolation of CD4þ T Cells
Peripheral blood mononuclear cells (PBMCs) were
isolated from whole blood by density gradient centri-
fugation. The anticoagulant used was either EDTA or
acid citrate dextrose. The cells were then cryopre-
served in 90% fetal bovine serum with 10% DMSO
and stored in liquid nitrogen until needed. All cells
were cryopreserved between November, 2007 and
October, 2011. Aliquots of frozen PBMCs were rap-
idly thawed and washed twice using 37˚C water-bath
warmed RPMI-1640 supplemented with 10% FBS.
Cells were resuspended in PBS containing 2% FBS,
and then aliquots were stained with trypan blue and
evaluated for cell viability and recoverability. The
CD4þ fraction of the total PBMCs was magnetically
labeled with CD4 Microbeads (Miltenyi Biotec, Cam-
bridge, MA). CD4þ cells were separated from the cell
suspension in a column within a magnetic field. The
column was then removed from the magnetic field,
and the purified cells were eluted as the positively
selected cell fraction and immediately processed for
RNA isolation. Sample purity was assessed by flow
cytometry, as described below.
Quantitative Real-Time PCR
To determine the gene expression levels of HSP90,
LEDGF/p75, p21/WAF1, and APOBEC3G in CD4þ
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cells, real-time PCR was carried out on cDNA reverse
transcribed (iScriptTM cDNA Synthesis Kit, Bio-Rad,
Hercules, CA) from RNA isolated from 1 to 8 106
purified CD4þ cells (AurumTM Total RNA Mini Kit,
Bio-Rad). One microgram of cDNA was then used as a
template for real-time PCR in a 7900HT Fast Real-
Time PCR System (ABI, Foster City, CA). The amplifi-
cation reactions were carried out in triplicate using
SsoAdvancedTM SYBR1 Green Supermix (Bio-Rad) in
25ml reaction volumes. The following primers were
used: HSP90 forward, 50-ATTTGTCCCACGACGTGCT-
CCTT-30; HSP90 reverse, 50-ATCCTCCGAGTCTACCA-
CCCCTCTAAT-30; LEDGF/p75 forward, 50-AGGCAGG-




CT-30; APOBEC3G forward, 50-ACCAGAAGCTTGGAG-
CAGAAAGTGA-30; APOBEC3G reverse, 50-ACGGTAT-
TCCGACGAGAAAGGATGGGT-30; Beta actin forward,
50-AGCCATGTACGTTGCTATCCAGGCT-30; Beta actin
reverse, 50-TCGGTGAGGATCTTCATGAGGTAGTCA-
GT-30. Beta actin was chosen as the reference/house-
keeping gene for this study based upon a previous
report showing that this gene is the most stably
expressed in PBMCs [Chege et al., 2010]. Primer
efficiencies were calculated using standard curves gen-
erated from 1:5 serial dilutions of an arbitrary sample
cDNA, using the calculation E¼ 10(1/slope). All primer
sets were validated to generate reproducible PCR
efficiencies between 90% and 100%. PCR conditions
consisted of a denaturation step at 95˚C for 30sec,
followed by 40 cycles of denaturation and annealing/
extension at 95˚C for 5sec and 55˚C for 30sec, respec-
tively, followed by dissociation curve analysis pro-
grammed by the ABI PCR System.
Flow Cytometry
To determine the purity of isolated CD4þ T cells,
purified cell samples were stained with PE-Cy7-
labeled antibody to CD3 and APC-labeled antibody to
CD4 (BD Biosciences, San Jose, CA), and then
analyzed by six-color flow cytometry. The purity of
sorted CD4þ T cells was identified according to the
percentages of CD3þ/CD4þ cells among total
PBMCs. For each subject 200,000 live-sorted cells
were stained for 30min with the anti-antibody cock-
tail at 4˚C in the dark in BD Falcon round bottom
tubes. After completion of the staining, cells were
washed with PBS and resuspended in an appropriate
volume of cold PBS. Acquisition of flow cytometry
data was performed on a FACSCanto A flow cytom-
eter (Becton Dickinson, Franklin Lakes, NJ) utilizing
FACSDiva Software Version 6.2. Electronic compen-
sation was performed with BD CompBeads (Becton
Dickinson) stained separately with individual mAbs.
Analyses were performed with FlowJo Version 9.4
software (Tree Star, Ashland, OR). The gating strat-
egy and background levels of staining were deter-
mined by utilizing Fluorescence Minus One with
Isotype controls.
Statistical Analysis
Descriptive statistics for demographic and clinical
characteristics regarding age at the time of speci-
men collection, sex, ethnicity (Hispanic, African
American, or Asian), CD4 counts (cells/ml), CD4
percentages, raltegravir/protease inhibitors treat-
ment status, viral RNA level (copies/ml), and peri-
natal/behavioral exposure status are reported in
Table I. It was investigated whether the mRNA
expression of HSP90, LEDGF/p75, p21/WAF1, and
APOBEC3G normalized to b-Actin varied signifi-
cantly due to the following parameters: sex (male
vs. female), ethnicity (Hispanic vs. Non-Hispanic),
infection status (uninfected vs. infected), ralte-
gravir/protease inhibitors treatment status (raltegra-
vir/protease inhibitors vs. non-raltegravir/non-
protease inhibitors), and viral load level among total
infected [viremic (100 copies/ml in this study) vs.
non-viremic subjects (<50 copies/ml)] and also specif-
ically among infected/untreated subjects (viral load
between 100 copies/ml and 1,000 copies/ml vs. viral
load 1,000 copies/ml). The expression of genes
HSP90, LEDGF/p75, p21/WAF1, and APOBEC3G
were measured in cycles to threshold (Ct), which
represented the cycle number at which the amount
of DNA reached an arbitrarily placed threshold
level. The normalized DCt values were obtained by
subtracting the Ct numbers of HSP90, LEDGF/p75,








Number participants 9 9 15 16
Median age, years (range) 30 (17–55) 24 (13–40) 35 (17–43) 14 (11–34)
Sex, % female 56 78 80 69
Ethnicity, % Hispanic 56 78 93 88
Median CD4þ count (range) 541 (338–942) 299 (23–713) 774 (405–976) —
Median CD4% (range) 23 (6.8–42) 21.1 (1.1–29.8) 32.6 (18–45.9) 43a (33.3–53.8)
Median viral RNA copies (range) 2,505 (129–1,880,000) 73,258 (11,776–172,136) <50 —
Number perinatally infected 0 5 3 —
Number behaviorally infected 9 4 12 —
aAmong 12 patients with CD4% data.
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p21/WAF1, and APOBEC3G from that of the refer-
ence gene, b-Actin. Scatter plots were constructed
for inspection of the Ct distribution of b-Actin for all
the participants (Fig. 2). Fold change, the expression
ratio, was then calculated using the following
method:
Fold change ¼ 2DDCt
where DDCt was the difference of the average DCt
values between two comparison groups.
Having a positive fold-change suggested that a
certain gene was upregulated, and a negative fold-
change suggested the opposite. The non-paramet-
ric Wilcoxon rank-sum test was performed to
determine whether the expression difference was
statistically significant. The associations between
ethnicity, gender, and HIV infection status were
modeled by linear regressions adjusted for age.
The normality of the residuals of all final models
was confirmed by histograms of residuals and
statistical tests of normality. The FDR approach
was used to adjust for multiple testing [Benjamini
et al., 2001].
RESULTS
Demographic and Clinical Characteristics of
Study Subjects
The demographic and clinical characteristics of
this study’s 49 participants are shown in Table I.
The infected/untreated and treated/non-viremic
subjects were older with a median age of 30 and 35
respectively, compared to uninfected individuals
with a median age of 14. Within the infected group,
25 participants were infected behaviorally and 8
perinatally. The infected/treated/non-viremic indi-
viduals had the highest median CD4 count (range:
405–976 cells/ml) and initial (pre-purification) CD4
percentage (range: 18–45.9%), while those in the
infected/treated/high viral load group had the low-
est CD4 count (range: 23–713 cells/ml) and initial
CD4 percentage (range: 1.1–29.8%). The infected/
untreated group included patients with low viral
loads (consistently <1,000 copies/ml for 3–16 years),
as well as those with much higher viral loads. This
group displayed a large viral load range from 129
to 1,880,000 copies/ml. The infected/treated/high vi-
ral load group had viral loads ranging from 11,776
to 172,136 copies/ml, as they were chosen to have
viral loads greater than 10,000 copies/ml. This
study’s design, illustrated in Figure 1, consisted of
purification of participants’ CD4þ cells from total
PBMCs and comparison of HSP90, LEDGF/p75,
p21/WAF1, and APOBEC3G gene expression with
respect to sex, ethnicity, infection status, viremic
status, raltegravir/protease inhibitor treatment,
and viral load.
Real-Time PCR Analysis of Host Gene
Expression in CD4þ T Cells from Infected and
Non-Infected Participants
To make conclusions about the significance of the
effect of certain parameters on the expression of HIV-
1 integration-modulating host genes, the normalized
expression (DCt) of different participant stratifica-
tions were compared, and the fold-change in gene
expression was calculated using the 2DDCt method.
The significance of difference in gene expression was
tested by the non-parametric Wilcoxon rank-sum test
using 0.05 P-value cut-off for significance (see
Tables II and III). Due to a high association between
age and HIV status among participants of this study,
DCt values were modeled by way of linear regressions
adjusted for age as a continuous variable, in which
gene expression was analyzed by Wald test (Table II).
As shown in Figure 2, b-Actin Ct values remained
relatively stable with respect to age in this cohort,
giving confidence in calculated variance for mRNA
levels of each of the genes of interest. No significant
difference in the expression of any of the four genes
with respect to sex, ethnicity, HIV exposure status or
mode of transmission was observed. In addition, viral
load level (100–1,000 copies/ml vs. 1,000 copies/ml)
among specifically the infected/untreated was not
associated with expression differences for any of the
four genes. In linear regression models adjusted for
age, mRNA expression levels of HSP90, LEDGF/p75,
and APOBEC3G were all slightly to moderately
decreased in infected patients with respect to unin-
fected individuals by 1.43-fold (P¼ 0.01), 1.26-fold
(P¼ 0.001), and 4.71-fold (P¼ 0.003), respectively.
Alternatively, p21/WAF1 expression was increased in
these patients by 2.35-fold (P¼ 0.03).
HSP90 mRNA expression was 1.48-fold lower in
infected/viremic patients than in infected/non-vire-
mic, while expressions of LEDGF/p75, p21/WAF1,
and APOBEC3G were similar in these two groups.
Furthermore, patients on raltegravir exhibited a
1.28-fold reduction in LEDGF/p75 mRNA expression
compared to those on non-raltegravir HAART
(P¼ 0.04). HSP90, APOBEC3G, and p21/WAF1 ex-
pressions were unaffected by raltegravir in reference
to non-raltegravir HAART. Also, among the treated
patients who were not on a raltegravir regimen, no
differences were observed in the expressions of all
four genes in infected subjects receiving protease
inhibitors compared to the patients receiving non-
protease inhibitor treatment (Table III).
DISCUSSION
HIV-1 propagation depends on a delicate balance
between cellular cofactors and restriction factors, and
multiple host proteins have been demonstrated to
facilitate or inhibit various stages of viral replication.
Furthermore, HIV-1 disease progression [Wu
et al., 2008; Vigneault et al., 2011] and response to
HAART [Woelk et al., 2010] have been shown to be
J. Med. Virol. DOI 10.1002/jmv
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associated with certain host cell gene expression
levels. Here, focus was placed on four host genes
(HSP90, LEDGF/p75, p21/WAF1, and APOBEC3G)
that have been described for their significant positive
or negative effects specifically on proviral integration.
Although all four of the genes studied here have been
individually analyzed in infected patients before,
there are some conflicting results [Jin et al., 2005;
Fig. 1. Scheme detailing subject panel construction, sample processing, and gene expression
analysis involved in this study.
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Cho et al., 2006; Ulenga et al., 2008; Reddy
et al., 2010]. Further, this study represents the first
time that these four genes have been scrutinized in
the same, well-characterized participant cohort.
HSP90 is a molecular chaperone that is one of the
most abundant proteins in the cell and assists in
proper protein folding and stabilization [Csermely
et al., 1998]. HSP90 has been well documented to
stabilize cellular proteins involved in tumor growth
[Kim et al., 2009] but has received relatively recent
attention as being important for HIV-1 proviral
integration [Vozzolo et al., 2010]. HSP90 protein
production has previously been shown to be de-
creased in infected patients [Yohannes et al., 2011],
and a minor but significant reduction in HSP90
mRNA levels was observed in this study, in infected
individuals. LEDGF/p75 is a known coactivator of
transcription [Ge et al., 1998; Fatma et al., 2001;
Singh et al., 2001] and normally protects cells from
thermal and oxidative stresses [Sharma et al., 2000;
Singh et al., 2000]. LEDGF/p75 has been designated
a cofactor of viral replication for its role in tethering
IN to host cell chromatin [Vanegas et al., 2005; Ciuffi
and Bushman, 2006; Hombrouck et al., 2007; Meehan
et al., 2009] and targeting integration into transcrip-
tionally active regions [Ciuffi et al., 2005, 2006 and
Shun et al., 2007]. Although LEDGF/p75 expression
was similar in viremic and non-viremic HIV patients,
its expression mirrored that of HSP90 with respect to
HIV infection status in general, with a 1.26-fold
reduction compared to healthy subjects. This observa-
tion correlates directly with a similar cross-sectional
study, which reported previously decreased LEDGF/
p75 in infected individuals [Mous et al., 2012].
The upregulation of p21/WAF1 that was observed
in this study in infected patients indicates that more
than just stress-related host genes may play a role in
this antiviral response. CD4þ T cells from elite
controllers have consistently exhibited increased p21/
WAF1 expression levels [Chen et al., 2011; Saez-
Cirion et al., 2011], and induction of p53 and its
target genes (including p21/WAF1) has been shown
to occur in microglia, astrocytes, and oligodendrocytes
as an adaptive response to HIV infection [Jayadev
et al., 2007]. Furthermore, p21/WAF1 expression has
been suggested to convey resistance to HIV-1 infec-
tion in hematopoietic stem cells through inactivation
of integrase [Zhang et al., 2007]. Here, infected
patients exhibited a 2.35-fold increase in p21/WAF1
mRNA expression relative to healthy individuals,
though its expression was similar in viremic and non-
viremic infected individuals. This data sheds light on
the possibility that HIV-1 infection modulates host
gene expression toward a potentially more extensive
antiviral response than is currently understood,
through decreasing production of host cofactors and
increasing production of host restriction factors. It is,
however, possible that the observed increase in p21/
WAF1 expression is actually HIV-induced rather
than host-induced, as p21/WAF1 is also an inhibitor
TABLE II. Analysis of Change in Gene Expression Relative to b-Actin Adjusting for Age


















Female 35 (71.4) Ref Ref Ref Ref
Male 14 (28.6) 1.05 0.68 1.02 0.69 1.14 0.70 1.73 0.23
Ethnicity 49
Hispanic 40 (83.3) Ref Ref Ref Ref
Not Hispanic 9 (18.4) 1.06 0.68 1.04 0.61 1.18 0.67 1.45 0.48
Infection status 49
Uninfected 16 (32.7) Ref Ref Ref Ref
Infected 33 (67.3) 1.43 0.01 1.26 0.001 2.35 0.03 4.71 0.003
Note: The fold changes were obtained from the 2DDCt method in multiplicative effect.
Ref, Reference group.
aLEDGF/p75 was transformed by the natural log in all models to better meet the residual normality criterion of linear regression.
The bold face highlights the significant p-values.
Fig. 2. Scatter plots representing b-Actin Ct distribution for
each subject and each subject respect to age in this study’s
participant cohort.
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of G1 and G2/M cell cycle phase transitions [Clark
et al., 2003] and has been shown to be upregulated
by HIV-1 Vpr as a means of stalling the cell cycle for
maximizing viral transcription prior to host cell
apoptosis [Goh et al., 1998]. This host gene has been
clearly shown to exert a dual positive and negative
effect on tumor growth [Stivala et al., 2012], and so
further work will be required to clarify whether p21/
WAF1 is exploited by the host cell as an antiviral
defense or by HIV itself for counteracting this
defense.
Alternatively, the mRNA expression of APOBEC3G,
another potent restriction factor of HIV-1 replication,
appears to be reduced by HIV infection in this patient
cohort. APOBEC3G is a cytidine deaminase that
decreases HIV-1 infectivity by inducing hypermuta-
tion of the viral genome [Sheehy et al., 2002; Wissing
et al., 2010] and interfering with integration through
IN-binding [Luo et al., 2007]. There has been some
controversy in the literature as to whether APO-
BEC3G is upregulated, downregulated, or unchanged
in infected individuals compared to healthy controls.
Two studies have reported that HIV-exposed sero-
negative individuals exhibit an increase in expression
compared to (A) healthy controls [Vazquez-Perez
et al., 2009] and (B) both healthy controls and
infected individuals [Biasin et al., 2007]. Alterna-
tively, there have been reports that APOBEC3G
expression is unchanged in exposed seronegative
individuals compared to healthy controls [Mous et al.,
2011], and also that its expression is reduced in
infected individuals compared to uninfected [Reddy
et al., 2010; Mous et al., 2012]. The results of this
study are in line with the latter studies, as a
significant decrease in APOBEC3G expression was
detected in infected individuals compared to unin-
fected. Furthermore, no difference was observed in
expression levels between exposed seronegative sub-
jects and healthy controls (data not shown). These
findings suggest that HIV can circumvent this natural
host restriction factor’s inhibitory action in its tran-
scription during infection. The further study of possi-
ble molecular mechanisms involved in such inhibition
may assist in developing novel strategies for new
drug targets. Most HIVþ patients, and especially co-
infected individuals, have skewed populations of T
cell subsets characterized by elevated levels of T cell
activation in their immune systems [Al-Harthi
et al., 2006]. As memory CD4þ T cells have shown
significantly different expression of certain genes
than naı¨ve CD4þ T cells, for example, expression of
APOBEC3G and LEDGF/p75 [Mous et al., 2011], fur-
ther work will be required to clarify how the homeo-
stasis of CD4þ T cells subsets, other viral co-
infections, and immune activation levels impact gene
expression in CD4þ T cell during HIV infection.
In summary a well-characterized panel of infected
and uninfected individuals was compiled in this
study, and the expressions of four host genes were
reported to positively or negatively affect the process
of HIV-1 proviral integration were analyzed. The age-
adjusted expression levels of HSP90, LEDGF/p75, and
APOBEC3G were all downregulated, while p21/WAF1
mRNA levels were upregulated due to HIV infection.
This work reveals that host genes exerting positive
effects on replication may be manipulated by the host
cell as an antiviral response, which is countered by
manipulation of alternate genes by the virus itself.
Elucidation of the complete mechanism underlying
the battle between host and virus is relevant for
future therapeutic efforts, and the genes scrutinized
in this work could potentially serve as novel drug
targets or biomarkers of disease progression.
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TABLE III. Analyses for Infected Participants Only, Not Adjusted for Age


















Non-viremic 15 (45.4) Ref Ref Ref Ref
Viremic 18 (54.6) 1.48 0.002 1.15 0.05 1.03 0.94 1.71 0.34
Among treated 21
Not on raltegravir 17 (81.0) Ref Ref Ref Ref
Raltegravir 4 (19.0) 1.39 0.19 1.28 0.04 1.12 0.85 3.54 0.16
Among non-raltegravir 17
Not on protease inhibitors 7 (41.2) Ref Ref Ref Ref
On protease inhibitors 10 (58.8) 1.17 0.49 1.14 0.21 1.20 0.71 3.87 0.07
Among untreated 9
Viral load 100–1,000 3 (33.3) Ref Ref Ref Ref
Viral load >1,000 6 (66.7) 1.00 1.00 1.16 0.36 2.07 0.36 4.39 0.28
Note: The fold changes were obtained from the 2DDCt method and the P-values were obtained from Wilcoxon rank-sum test.
Ref, Reference group.
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